289 related articles for article (PubMed ID: 20074280)
1. Blocking interleukin-1 in rheumatic diseases.
Goldbach-Mansky R
Ann N Y Acad Sci; 2009 Dec; 1182():111-23. PubMed ID: 20074280
[TBL] [Abstract][Full Text] [Related]
2. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.
Goldbach-Mansky R
Clin Exp Immunol; 2012 Mar; 167(3):391-404. PubMed ID: 22288582
[TBL] [Abstract][Full Text] [Related]
3. IL-1 blockade in autoinflammatory syndromes.
Jesus AA; Goldbach-Mansky R
Annu Rev Med; 2014; 65():223-44. PubMed ID: 24422572
[TBL] [Abstract][Full Text] [Related]
4. [IL-1 antagonists].
Kötter I; Horneff G
Z Rheumatol; 2010 Sep; 69(7):581-93. PubMed ID: 20703489
[TBL] [Abstract][Full Text] [Related]
5. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
6. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
Cavalli G; Dinarello CA
Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
8. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-1 molecules: new comers and new indications.
Moltó A; Olivé A
Joint Bone Spine; 2010 Mar; 77(2):102-7. PubMed ID: 20045371
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
11. The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment.
Lopalco G; Rigante D; Cantarini L; Imazio M; Lopalco A; Emmi G; Venerito V; Fornaro M; Frediani B; Nivuori M; Brucato A; Iannone F
Trends Cardiovasc Med; 2021 Jul; 31(5):265-274. PubMed ID: 32376492
[TBL] [Abstract][Full Text] [Related]
12. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
Geyer M; Müller-Ladner U
Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
[TBL] [Abstract][Full Text] [Related]
13. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.
Malcova H; Strizova Z; Milota T; Striz I; Sediva A; Cebecauerova D; Horvath R
Front Immunol; 2020; 11():619257. PubMed ID: 33603750
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin-1 inhibitors in the management of gout.
Tran TH; Pham JT; Shafeeq H; Manigault KR; Arya V
Pharmacotherapy; 2013 Jul; 33(7):744-53. PubMed ID: 23553601
[TBL] [Abstract][Full Text] [Related]
16. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
Guignard S; Dien G; Dougados M
Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
[TBL] [Abstract][Full Text] [Related]
17. Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades.
Eskola V; Pohjankoski H; Kröger L; Aalto K; Latva K; Korppi M
Acta Paediatr; 2018 Apr; 107(4):577-580. PubMed ID: 29331074
[TBL] [Abstract][Full Text] [Related]
18. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
19. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
Dinarello CA; Simon A; van der Meer JW
Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
Lopalco G; Rigante D; Giannini M; Galeazzi M; Lapadula G; Iannone F; Cantarini L
Clin Exp Rheumatol; 2016; 34(3):531-8. PubMed ID: 26940286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
